Critical Contribution of OX40 Ligand to T Helper Cell Type 2 Differentiation in Experimental Leishmaniasis

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2000 Jan 19

PMID 10637281

Citations 67

Authors

H Akiba

Y Miyahira

M Atsuta

K Takeda

C Nohara

T Futagawa

H Matsuda

T Aoki

H Yagita

K Okumura

Affiliations

Soon will be listed here.

Abstract

Infection of inbred mouse strains with Leishmania major is a well characterized model for analysis of T helper (Th)1 and Th2 cell development in vivo. In this study, to address the role of costimulatory molecules CD27, CD30, 4-1BB, and OX40, which belong to the tumor necrosis factor receptor superfamily, in the development of Th1 and Th2 cells in vivo, we administered monoclonal antibody (mAb) against their ligands, CD70, CD30 ligand (L), 4-1BBL, and OX40L, to mice infected with L. major. Whereas anti-CD70, anti-CD30L, and anti-4-1BBL mAb exhibited no effect in either susceptible BALB/c or resistant C57BL/6 mice, the administration of anti-OX40L mAb abrogated progressive disease in BALB/c mice. Flow cytometric analysis indicated that OX40 was expressed on CD4(+) T cells and OX40L was expressed on CD11c(+) dendritic cells in the popliteal lymph nodes of L. major-infected BALB/c mice. In vitro stimulation of these CD4(+) T cells showed that anti-OX40L mAb treatment resulted in substantially reduced production of Th2 cytokines. Moreover, this change in cytokine levels was associated with reduced levels of anti-L. major immunoglobulin (Ig)G1 and serum IgE. These results indicate that anti-OX40L mAb abrogated progressive leishmaniasis in BALB/c mice by suppressing the development of Th2 responses, substantiating a critical role of OX40-OX40L interaction in Th2 development in vivo.

Citing Articles

Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes.

Sato A, Nagai H, Suzuki A, Ito A, Matsuyama S, Shibui N Front Immunol. 2025; 15:1473815.

PMID: 39867912 PMC: 11757143. DOI: 10.3389/fimmu.2024.1473815.

Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis.

Lafleur A, Daffis S, Mowbray C, Arana B Vaccines (Basel). 2024; 12(10).

PMID: 39460345 PMC: 11511131. DOI: 10.3390/vaccines12101179.

Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking.

Liu L, Wu Y, Ye K, Cai M, Zhuang G, Wang J Front Pharmacol. 2022; 13:924197.

PMID: 35865955 PMC: 9295861. DOI: 10.3389/fphar.2022.924197.

Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis.

Dey N, Senaratne S, Somaratne V, Madarasinghe N, Seneviratne B, Forrester S J Clin Invest. 2021; 131(22).

PMID: 34609968 PMC: 8592550. DOI: 10.1172/JCI142765.

Recent advances in understanding the role of IL-4 signaling.

Keegan A, Leonard W, Zhu J Fac Rev. 2021; 10:71.

PMID: 34557875 PMC: 8442009. DOI: 10.12703/r/10-71.

References

OGarra A . Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity. 1998; 8(3):275-83. DOI: 10.1016/s1074-7613(00)80533-6. View

Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G . Expression and function of OX40 ligand on human dendritic cells. J Immunol. 1997; 159(8):3838-48. View

Oshima H, Nakano H, Nohara C, Kobata T, Nakajima A, Jenkins N . Characterization of murine CD70 by molecular cloning and mAb. Int Immunol. 1998; 10(4):517-26. DOI: 10.1093/intimm/10.4.517. View

Flynn S, Toellner K, Raykundalia C, Goodall M, Lane P . CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med. 1998; 188(2):297-304. PMC: 2212448. DOI: 10.1084/jem.188.2.297. View

von Stebut E, Belkaid Y, Jakob T, Sacks D, Udey M . Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J Exp Med. 1998; 188(8):1547-52. PMC: 2213412. DOI: 10.1084/jem.188.8.1547. View

Ohshima Y, Yang L, Uchiyama T, Tanaka Y, Baum P, Sergerie M . OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood. 1998; 92(9):3338-45. View

Higgins L, McDonald S, Whittle N, Crockett N, Shields J, MacDonald T . Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol. 1999; 162(1):486-93. View

Maldonado-Lopez R, De Smedt T, Michel P, Godfroid J, Pajak B, Heirman C . CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med. 1999; 189(3):587-92. PMC: 2192907. DOI: 10.1084/jem.189.3.587. View

Weinberg A, Wegmann K, Funatake C, WHITHAM R . Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol. 1999; 162(3):1818-26. View

10.

Shimozato O, Takeda K, Yagita H, Okumura K . Expression of CD30 ligand (CD153) on murine activated T cells. Biochem Biophys Res Commun. 1999; 256(3):519-26. DOI: 10.1006/bbrc.1999.0336. View

11.

Brocker T, Flynn S, Riedinger M, Raykundalia C, Lane P . CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur J Immunol. 1999; 29(5):1610-6. DOI: 10.1002/(SICI)1521-4141(199905)29:05<1610::AID-IMMU1610>3.0.CO;2-8. View

12.

Akiba H, Oshima H, Takeda K, Atsuta M, Nakano H, Nakajima A . CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J Immunol. 1999; 162(12):7058-66. View

13.

Azuma M, Hirano T, Miyajima H, Watanabe N, Yagita H, Enomoto S . Regulation of murine IgE production in SJA/9 and nude mice. Potentiation of IgE production by recombinant interleukin 4. J Immunol. 1987; 139(8):2538-44. View

14.

Crowley M, Inaba K, Steinman R . The cell surface of mouse dendritic cells: FACS analyses of dendritic cells from different tissues including thymus. Cell Immunol. 1989; 118(1):108-25. DOI: 10.1016/0008-8749(89)90361-4. View

15.

Sugita K, Torimoto Y, Nojima Y, Daley J, Schlossman S, Morimoto C . The 1A4 molecule (CD27) is involved in T cell activation. J Immunol. 1991; 147(5):1477-83. View

16.

Chatelain R, Varkila K, Coffman R . IL-4 induces a Th2 response in Leishmania major-infected mice. J Immunol. 1992; 148(4):1182-7. View

17.

Will A, Blank C, Rollinghoff M, Moll H . Murine epidermal Langerhans cells are potent stimulators of an antigen-specific T cell response to Leishmania major, the cause of cutaneous leishmaniasis. Eur J Immunol. 1992; 22(6):1341-7. DOI: 10.1002/eji.1830220603. View

18.

Smith C, Farrah T, Goodwin R . The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994; 76(6):959-62. DOI: 10.1016/0092-8674(94)90372-7. View

19.

Wang Z, Reiner S, Zheng S, Dalton D, Locksley R . CD4+ effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major. J Exp Med. 1994; 179(4):1367-71. PMC: 2191434. DOI: 10.1084/jem.179.4.1367. View

20.

Del Prete G, De Carli M, Almerigogna F, Daniel C, DElios M, Zancuoghi G . Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J. 1995; 9(1):81-6. View